FINWIRES · TerminalLIVE
FINWIRES

周四欧洲股市下跌;投资者对中东和平前景仍持谨慎态度

By

-- 周四,欧洲股市普遍走低,投资者对美伊可能达成的和平协议以及霍尔木兹海峡的重新开放仍持谨慎态度。 斯托克欧洲指数下跌0.8%,德国DAX指数下跌0.7%,英国富时100指数下跌1.4%,法国CAC40指数下跌0.8%,瑞士市场指数下跌0.9%。 矿业、汽车和奢侈品类股走高,而油价下跌拖累能源类股走低。 企业新闻方面,据彭博社周四报道,摩纳哥金融安全局(AMSF)因瑞银集团在反洗钱政策方面存在某些缺陷,对其处以700万欧元(约合820万美元)的罚款。 报告指出,这些失误包括基于过时且未经翻译的俄语文件接纳新客户,以及未能妥善审查与高风险地区相关的交易。 瑞银集团和奥地利金融市场管理局(AMSF)尚未回复的置评请求。 这家瑞士银行在苏黎世的股价下跌了0.4%。 壳牌公司周四公布了第一季度调整后每股收益为1.22美元,高于去年同期的0.92美元。FactSet调查的分析师此前预期为1.04美元。 截至3月31日的第一季度,壳牌公司营收为696.9亿美元,高于去年同期的692.3亿美元。FactSet调查的分析师此前预期为814亿美元。 该公司还启动了一项30亿美元的股票回购计划,并将季度中期股息提高5%至每股0.3906美元,将于6月29日支付给截至5月22日登记在册的股东。 这家英国油气公司的股价在伦敦下跌了3.3%。 BioNTech公司周四表示,已批准一项新的10亿美元股票回购计划,用于回购其美国存托凭证(ADS)。 这家德国生物技术公司表示,该计划将持续到2027年5月6日(含当日)。 BioNTech的股价在法兰克福下跌不到0.1%。 埃尼公司周四表示,其在印度尼西亚近海的Geliga-1油田的钻杆测试结果强劲,证实了该油田储层产能充足,并凸显了库泰盆地的战略意义。 在测试期间,该井的日产量高达6000万标准立方英尺,受限于钻井平台产能和最小压降。埃尼公司估计,该油井可持续日产天然气约2亿标准立方英尺,凝析油约1万桶。 这家意大利石油天然气公司的股票在米兰下跌了2.8%。

Related Articles

Research

Research Alert: CFRA Upgrades Opinion On Shares Of Mcdonald's Corp To Buy From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target by $33 to $317, 24x our 2026 EPS estimate and in line with the shares' ten-year average forward multiple. We lower our 2026 EPS view to $13.21 from $13.44 and 2027's to $14.11 from $14.27. We upgrade MCD from Hold to Buy. Shares trade at a 12% discount to their ten-year forward average, creating an attractive entry point despite near-term margin headwinds from restaurant operating costs, particularly beef costs. We expect margin normalization as traffic gains scale and value messaging matures. Q1 results outperformed on total revenue, global comps, and adjusted EPS, with developed market comps of +3.9%, improving 490 bps sequentially, and developing markets maintaining momentum at +3.4%. In our view, results suggest value positioning is resonating globally and driving traffic recovery. MCD's category expansion into chicken and beverages provides incremental growth optionality, while >80% free cash flow conversion supports continued investment in restaurant development and shareholder returns.

$MCD
Research

Research Alert: CFRA Keeps Hold View On Shares Of Kenvue Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target price at $19, which is 16.5x our 2027 EPS view of $1.15, a discount to the trading multiple of 18.1x since going public in 2023. We think this multiple is justified given the litigation overhang and limited visibility into KVUE's standalone performance (the company is no longer providing forward-looking guidance and hosting an analyst call) due to the pending acquisition by Kimberly-Clark (KMB), expected to close during 2H 2026. We increase our 2026 EPS estimate to $1.15 from $1.10 following this morning's Q1 earnings release. We maintain our 2027 EPS estimate at $1.15. Kenvue delivered a solid first quarter that demonstrated continued operational momentum. Net sales increased to $3,909M (+4.5% Y/Y) with organic growth of 0.7%. The performance suggests management's operational initiatives are gaining traction as the company approaches the transaction close. The transaction received shareholder approval in January 2026, and regulatory approvals are progressing.

$KVUE
Sectors

Sector Update: Health Care Stocks Decline in Afternoon Trading

Health care stocks declined Thursday afternoon with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.6%.In corporate news, Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.2% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA